Kyverna Therapeutics (KYTX) Common Equity (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Common Equity came in at $195.6 million in Q1 2026, down 12.69% YoY from $224.0 million in Q1 2025, and down 15.8% on a QoQ basis from $232.3 million in Q4 2025.
Kyverna Therapeutics (KYTX) Common Equity (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Common Equity data on file, last reported at $195.6 million in Q1 2026.
- Quarterly Common Equity fell 12.69% year-over-year to $195.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $195.6 million (down 12.69% YoY) and the FY2025 annual result came in at $232.3 million, down 12.87% from the prior year.
- Common Equity fell to $195.6 million in Q1 2026, from $232.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $361.0 million in Q1 2024 to a low of -$131.4 million in Q4 2023.
- A 4-year average of $140.5 million and a median of $195.6 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity soared 526.64% — and 2025, when it plunged 49.8%.
- Tracing KYTX's Common Equity over 4 years: stood at -$131.4 million in 2023, then surged by 302.89% to $266.6 million in 2024, then fell by 12.87% to $232.3 million in 2025, then decreased by 15.8% to $195.6 million in 2026.
- The last three Common Equity figures came in at $195.6 million (Q1 2026), $232.3 million (Q4 2025), and $151.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 165.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165.55 Mn |
| Mar 31, 2026 | 195.58 Mn |
| Dec 31, 2025 | 232.28 Mn |
| Sep 30, 2025 | 151.95 Mn |
| Jun 30, 2025 | 184.38 Mn |
| Mar 31, 2025 | 224.01 Mn |
| Dec 31, 2024 | 266.59 Mn |
| Sep 30, 2024 | 302.71 Mn |
| Jun 30, 2024 | 333.51 Mn |
| Mar 31, 2024 | 360.99 Mn |
| Dec 31, 2023 | -131.40 Mn |
| Sep 30, 2023 | -111.81 Mn |
| Jun 30, 2023 | -97.20 Mn |
| Mar 31, 2023 | -84.61 Mn |